A Zeyfang1,2. 1. AGAPLESION Bethesda Krankenhaus Stuttgart, Hohenheimerstr. 21, 70184, Stuttgart, Deutschland. andrej.zeyfang@bethesda-stuttgart.de. 2. Institut für Epidemiologie, Universität Ulm, Albert-Einstein-Allee 41, 89081, Ulm, Deutschland. andrej.zeyfang@bethesda-stuttgart.de.
Abstract
BACKGROUND: A majority of older people with type 2 diabetes are multimorbid, frail or have limitations in functions. Polypharmacotherapy is unfortunately a frequent occurrence and dangerous. In particular the administration of antihyperglycemic therapy must be carefully weighed up against the risks associated with hypoglycemia. AIM: The conditions and characteristics of older persons with diabetes are highlighted with respect to the use of individualized therapy of diabetes. RESULTS AND CONCLUSION: The advantages and disadvantages of oral antidiabetic agents, insulins and substances with novel active principles, such as gliflozin drugs are discussed. Established oral therapeutic drugs, such as metformin as well as the new substance groups, such as gliptins are advantageous in this patient group. Injection-based therapies with glucagon-like peptide 1 (GLP-1) mimetics and the new insulins can also expand the spectrum of therapy if they are prudently used.
BACKGROUND: A majority of older people with type 2 diabetes are multimorbid, frail or have limitations in functions. Polypharmacotherapy is unfortunately a frequent occurrence and dangerous. In particular the administration of antihyperglycemic therapy must be carefully weighed up against the risks associated with hypoglycemia. AIM: The conditions and characteristics of older persons with diabetes are highlighted with respect to the use of individualized therapy of diabetes. RESULTS AND CONCLUSION: The advantages and disadvantages of oral antidiabetic agents, insulins and substances with novel active principles, such as gliflozin drugs are discussed. Established oral therapeutic drugs, such as metformin as well as the new substance groups, such as gliptins are advantageous in this patient group. Injection-based therapies with glucagon-like peptide 1 (GLP-1) mimetics and the new insulins can also expand the spectrum of therapy if they are prudently used.
Authors: Reinhard H A Becker; Raphael Dahmen; Karin Bergmann; Anne Lehmann; Thomas Jax; Tim Heise Journal: Diabetes Care Date: 2014-08-22 Impact factor: 19.112
Authors: Ulrik Madvig Mogensen; Charlotte Andersson; Emil Loldrup Fosbøl; Tina Ken Schramm; Allan Vaag; Nikolai Madrid Scheller; Christian Torp-Pedersen; Gunnar Gislason; Lars Køber Journal: Diabetes Res Clin Pract Date: 2014-10-07 Impact factor: 5.602
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: Tao Xu; Stefan Brandmaier; Ana C Messias; Christian Herder; Harmen H M Draisma; Ayse Demirkan; Zhonghao Yu; Janina S Ried; Toomas Haller; Margit Heier; Monica Campillos; Gisela Fobo; Renee Stark; Christina Holzapfel; Jonathan Adam; Shen Chi; Markus Rotter; Tommaso Panni; Anne S Quante; Ying He; Cornelia Prehn; Werner Roemisch-Margl; Gabi Kastenmüller; Gonneke Willemsen; René Pool; Katarina Kasa; Ko Willems van Dijk; Thomas Hankemeier; Christa Meisinger; Barbara Thorand; Andreas Ruepp; Martin Hrabé de Angelis; Yixue Li; H-Erich Wichmann; Bernd Stratmann; Konstantin Strauch; Andres Metspalu; Christian Gieger; Karsten Suhre; Jerzy Adamski; Thomas Illig; Wolfgang Rathmann; Michael Roden; Annette Peters; Cornelia M van Duijn; Dorret I Boomsma; Thomas Meitinger; Rui Wang-Sattler Journal: Diabetes Care Date: 2015-08-05 Impact factor: 19.112
Authors: D G Bruce; W A Davis; G P Casey; R M Clarnette; S G A Brown; I G Jacobs; O P Almeida; T M E Davis Journal: Diabetologia Date: 2009-07-03 Impact factor: 10.122
Authors: Suellen M Curkendall; Nina Thomas; Kelly F Bell; Paul L Juneau; Audrey J Weiss Journal: Curr Med Res Opin Date: 2013-07-23 Impact factor: 2.580
Authors: Claudia Bollig; Gabriel Torbahn; Jürgen Bauer; Simone Brefka; Dhayana Dallmeier; Michael Denkinger; Annette Eidam; Stefan Klöppel; Andrej Zeyfang; Sebastian Voigt-Radloff Journal: Z Gerontol Geriatr Date: 2020-04-17 Impact factor: 1.281